ArticleRadiology2025
Calcifications Affect Pathologic Complete Response and MRI Prediction after Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2-positive Breast Cancer.
Article in Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Response-Adapted Surgery for Residual Calcifications in HER2-Positive Breast Cancer After Neoadjuvant Chemotherapy.Journal of breast cancer · 2026Article
- MRI quantification of intratumoral heterogeneity for predicting HER2-positive status in breast cancer: a retrospective multicenter study.BMC cancer · 2026Article
- Mammographic Calcifications Add Uncertainty in Predicting Response to Neoadjuvant Chemotherapy.Radiology · 2025Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The optimal surgical management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer with calcifications remains controversial, particularly when pathologic complete response (pCR) is suspected. Purpose To identify factors associated with pCR after neoadjuvant chemotherapy in patients with HER2-positive breast cancer and assess whether calcifications affect the performance of radiologic complete response (rCR) at MRI for predicting pCR. Materials and Methods This retrospective study included patients with HER2-positive breast cancer who received neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab and underwent surgery between January 2021 and October 2023. The association of clinicopathologic factors and imaging features at mammography and MRI with pCR was analyzed using logistic regression. The diagnostic performance of rCR at MRI for predicting pCR was compared between patients with and without calcifications using the χ
Indexed as
Identifiers
40923884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.